Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp

Munich, Germany 29.06.22 – We are pleased to announce the launch of OMCAT*, the largest AI clinical trial in oncology. The vision behind this trial is to sustainably improve the care and safety of cancer patients. One million cancer treatment months will be recorded based on 166,000 patient data in order to train an AI in this way. By using innovative methods and artificial intelligence, it will be possible to predict therapy events in the future. To realize this, OMCAT includes the detailed documentation of these events through the digital health application (DiGA) PRO-React Onco. This has already been approved by the Federal Institute for Drugs and Medical Devices (BfArM) as a digital health application since 05/2021. Consequently, cost coverage by the statutory health insurances is possible.

The speed with which we were able to proceed from the project initiation to the start of the trial speaks for the high level of commitment of all those involved with the goal of revolutionizing therapy management and providing patients with the best possible support. 

If you would also like to help shape the medicine of tomorrow and become part of OMCAT, please feel free to contact us at:


CANKADO ePRO is trusted by

Want to know more?

Contact us to know more about our products and we’ll answer all your queries.

CANKADO processes information about your visit on this website using cookies. These are required to ensure the correct functionality of the homepage, to improve its performance and our third-party services. These services cannot be used without your consent.